The estimated Net Worth of Kathryn E Falberg is at least $79.5 Миллион dollars as of 13 August 2024. Ms. Falberg owns over 150,000 units of UroGen Pharma Ltd stock worth over $1,338,327 and over the last 16 years she sold URGN stock worth over $77,864,159. In addition, she makes $332,698 as Independent Director at UroGen Pharma Ltd.
Kathryn has made over 39 trades of the UroGen Pharma Ltd stock since 2010, according to the Form 4 filled with the SEC. Most recently she sold 150,000 units of URGN stock worth $14,725,500 on 13 August 2024.
The largest trade she's ever made was selling 150,000 units of UroGen Pharma Ltd stock on 13 August 2024 worth over $14,725,500. On average, Kathryn trades about 15,616 units every 54 days since 2008. As of 13 August 2024 she still owns at least 96,910 units of UroGen Pharma Ltd stock.
You can see the complete history of Ms. Falberg stock trades at the bottom of the page.
Kathryn E. Falberg is Independent Director of the Company. She previously served as Executive Vice President and Chief Financial Officer of Jazz Pharmaceuticals plc, a multi-national specialty biopharmaceutical company, from March 2012 to March 2014 after serving as Senior Vice President and Chief Financial Officer since December 2009. Her responsibilities at Jazz Pharmaceuticals included strategy, corporate development, corporate communications and information technology. From 2001 through 2009, Ms. Falberg served as a corporate director and audit committee chair for several companies. From 1995 to 2001, Ms. Falberg was with Amgen Inc., a biotechnology company, where she served as Senior Vice President, Strategy and Chief Financial Officer and prior to that as Vice President, Corporate Controller and Chief Accounting Officer, and Vice President, Treasurer. Ms. Falberg also serves as a member of the boards of directors of biopharmaceutical companies Aimmune Therapeutics, Inc., Arcus Biosciences, Inc. and Tricida Inc. Ms. Falberg also serves as a member of the board of directors of The Trade Desk, Inc., a technology company. Ms. Falberg previously served on the boards of directors of Axovant Sciences, Ltd., BioMarin Pharmaceutical Inc., Medivation Inc., Halozyme Therapeutics, Inc., aTyr Pharma, Inc., and multiple other companies. Ms. Falberg received an M.B.A. in Finance and B.A., in Economics from the University of California, Los Angeles and is a certified public accountant (inactive). Our Board believes Ms. Falberg’s financial knowledge and experience qualifies her to serve on our board of directors.
As the Independent Director of UroGen Pharma Ltd, the total compensation of Kathryn Falberg at UroGen Pharma Ltd is $332,698. There are 8 executives at UroGen Pharma Ltd getting paid more, with Elizabeth Barrett having the highest compensation of $25,900,800.
Kathryn Falberg is 59, she's been the Independent Director of UroGen Pharma Ltd since 2017. There are 6 older and 8 younger executives at UroGen Pharma Ltd. The oldest executive at UroGen Pharma Ltd is Stuart Holden, 77, who is the Independent Director.
Kathryn's mailing address filed with the SEC is C/O THE TRADE DESK, INC., 42 NORTH CHESTNUT STREET, VENTURA, CA, 93001.
Over the last 7 years, insiders at UroGen Pharma Ltd have traded over $8,740,363 worth of UroGen Pharma Ltd stock and bought 33,940 units worth $791,524 . The most active insiders traders include Ran Nussbaum, Arie Belldegrun и Kathryn E Falberg. On average, UroGen Pharma Ltd executives and independent directors trade stock every 31 days with the average trade being worth of $214,027. The most recent stock trade was executed by Mark Schoenberg on 10 June 2024, trading 10,000 units of URGN stock currently worth $138,100.
urogen pharma ltd. (nasdaq:urgn) is a clinical-stage biopharmaceutical company developing advanced non-surgical treatments to address unmet needs in the field of urology, with a focus on uro-oncology. the company has developed rtgel™, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. urogen pharma's sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. urogen pharma's lead product candidates, mitogel™ (mitomycin urothelial gel) and vesigel™ (mitomycin intravesical gel), are designed to potentially remove tumors by non-surgical means and to treat several forms of non-muscle invasive urothelial cancer, including low-grade upper tract urothelial carcinoma and bladder cancer, respectively. urogen pharma is headquartered in ra’anana, israel with u.s. headquarters in new york.
UroGen Pharma Ltd executives and other stock owners filed with the SEC include: